Abstract
The cotton rat Sigmodon hispidus is a New World rodent that has become an important model of respiratory syncytial virus (RSV) infection. This small animal is relatively permissive to RSV and can be infected throughout life. It recapitulates the pathology associated with the FI-RSV vaccine-enhanced disease, the phenomenon of maternally transmitted immunity and the ability of passive immunity to suppress efficacy of RSV vaccines. Different highly susceptible human cohort scenarios have been modeled in the cotton rat, including RSV disease in infants, elderly, and immunosuppressed individuals. The cotton rat has accurately predicted efficacy and dose of antibody immunoprophylaxis, and the lack of efficacy of antibody immunotherapy for disease treatment. With the recent development of molecular reagents and tools for the model, the cotton rat is an important model of RSV infection to consider for vaccine and drug testing, and will continue to advance our understanding of RSV disease pathogenesis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Blanco JC, Richardson JY, Darnell ME et al (2002) Cytokine and chemokine gene expression after primary and secondary respiratory syncytial virus infection in cotton rats. J Infect Dis 185(12):1780–1785
Blanco JC, Pletneva L, Boukhvalova M, Richardson JY, Harris KA, Prince GA (2004) The cotton rat: an underutilized animal model for human infectious diseases can now be exploited using specific reagents to cytokines, chemokines, and interferons. J Interferon Cytokine Res 24(1):21–28
Blanco J et al (2011) The quest for a small animal model for HIV infection and disease. In: Chang TL (ed) HIV-host interactions, vol. Chapter 14 INTECH Open Access Publisher, p 349
Blanco JC, Plentneva LM, Wan H et al (2013) Receptor characterization and susceptibility of cotton rats to avian and 2009 pandemic influenza virus strains. J Virol 87(4):2036–2045
Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, Blanco JC (2006) The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine 24(23):5027–5035
Boukhvalova MS, Prince GA, Blanco JC (2007a) Respiratory syncytial virus infects and abortively replicates in the lungs in spite of preexisting immunity. J Virol 81(17):9443–9450
Boukhvalova MS, Prince GA, Blanco JC (2009) The cotton rat model of respiratory viral infections. Biologicals 37(3):152–159
Boukhvalova MS, Sotomayor TB, Point RC, Pletneva LM, Prince GA, Blanco JC (2010) Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model. J Interferon Cytokine Res 30(4):229–242
Boukhvalova MS, Yim KC, Kuhn KH et al (2007b) Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment. J Infect Dis 195(4):511–518
Curtis SJ, Ottolini MG, Porter DD, Prince GA (2002) Age-dependent replication of respiratory syncytial virus in the cotton rat. Exp Biol Med (Maywood) 227(9):799–802
Dreizin RS, Vyshnevetskaia LO, Bagdamian EE, Iankevich OD, Tarasova LB (1971) Experimental RS virus infection of cotton rats. a viral and immunofluorescent study. Vopr Virusol 16(6):670–676
Falsey AR (2005) Respiratory syncytial virus infection in elderly and high-risk adults. Exp Lung Res 31(Suppl 1):77
Malley R, DeVincenzo J, Ramilo O et al (1998) Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 178(6):1555–1561
Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA (1990) Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization. Vaccine 8(5):497–502
Murphy BR, Graham BS, Prince GA et al (1986b) Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol 23(6):1009–1014
Murphy BR, Prince GA, Walsh EE et al (1986a) Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 24(2):197–202
Niewiesk S, Prince G (2002) Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases. Lab Anim 36(4):357–372
Ottolini MG, Porter DD, Hemming VG, Zimmerman MN, Schwab NM, Prince GA (1999) Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant 24(1):41–45
Parrott RH, Kim HW, Arrobio JO et al (1973) Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 98(4):289–300
Pletneva LM, Haller O, Porter DD, Prince GA, Blanco JC (2006) Interferon-inducible Mx gene expression in cotton rats: cloning, characterization, and expression during influenza viral infection. J Interferon Cytokine Res 26(12):914–921
Pletneva LM, Haller O, Porter DD, Prince GA, Blanco JC (2008) Induction of type I interferons and interferon-inducible Mx genes during respiratory syncytial virus infection and reinfection in cotton rats. J Gen Virol 89(Pt 1):261–270
Prince GA, Denamur F, Deschamps M et al (2001b) Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine 19(15–16):2048–2054
Prince GA, Mond JJ, Porter DD, Yim KC, Lan SJ, Klinman DM (2003) Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol 77(24):13156–13160
Prince GA, Potash L, Horswood RL et al (1979b) Intramuscular inoculation of live respiratory syncytial virus induces immunity in cotton rats. Infect Immun 23(3):723–728
Prince GA, Horswood RL, Camargo E, Suffin SC, Chanock RM (1982) Parenteral immunization with live respiratory syncytial virus is blocked in seropositive cotton rats. Infect Immun 37(3):1074–1078
Prince GA, Porter DD (1976) The pathogenesis of respiratory syncytial virus infection in infant ferrets. Am J Pathol 82(2):339–352
Prince GA, Horswood RL, Berndt J, Suffin SC, Chanock RM (1979a) Respiratory syncytial virus infection in inbred mice. Infect Immun 26(2):764–766
Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM (1978) The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 93(3):771–791
Prince GA, Jenson AB, Hemming VG et al (1986) Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol 57(3):721–728
Prince GA, Prieels JP, Slaoui M, Porter DD (1999) Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus). Lab Invest 79(11):1385–1392
Prince GA, Hemming VG, Horswood RL, Chanock RM (1985a) Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res 3(3):193–206
Prince GA, Horswood RL, Camargo E, Koenig D, Chanock RM (1983) Mechanisms of immunity to respiratory syncytial virus in cotton rats. Infect Immun 42(1):81–87
Prince GA, Horswood RL, Chanock RM (1985b) Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 55(3):517–520
Prince GA, Curtis SJ, Yim KC, Porter DD (2001a) Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82(Pt 12):2881–2888
Prince G, Mathews A, Curtis S, Porter DD (2000) Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model with systemically administered monoclonal antibody (palivizumab) and glucocorticosteroid. J Infect Dis 182:1326–1330
Richardson JY, Ottolini MG, Pletneva L et al (2005) Respiratory syncytial virus (RSV) infection induces cyclooxygenase 2: a potential target for RSV therapy. J Immunol 174(7):4356–4364
Rodriguez WJ, Gruber WC, Welliver RC et al (1997) Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: respiratory syncytial virus immune globulin study group. Pediatrics 99(3):454–461
Shirey KA, Pletneva LM, Puche AC et al (2010) Control of RSV-induced lung injury by alternatively activated macrophages is IL-4R alpha-, TLR4-, and IFN-beta-dependent. Mucosal Immunol 3(3):291–300
Siber GR, Leombruno D, Leszczynski J et al (1994) Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 169(6):1368–1373
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Boukhvalova, M.S., Blanco, J.C.G. (2013). The Cotton Rat Sigmodon Hispidus Model of Respiratory Syncytial Virus Infection. In: Anderson, L., Graham, B. (eds) Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Current Topics in Microbiology and Immunology, vol 372. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38919-1_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-38919-1_17
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-38918-4
Online ISBN: 978-3-642-38919-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)